However, clinical trials utilizing anti-IL17A monoclonal antibodies (secukinumab) for Crohn’s disease treatment demonstrated that the blockade of IL-17A was ineffective and, moreover, resulted in increased frequency of fungal infections, suggesting the protective function of IL-17A in the context of intestinal immunity [186]. Here, IL17A is linked to fungal infectious disease.